LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Затворен

4.57 0.22

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.5600000000000005

Максимум

4.58

Ключови измерители
By Trading Economics
Служители	26

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	14M 34M
Предишно отваряне	4.35
Предишно затваряне	4.57

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.02.2026 г., 22:17 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1st Half Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.02.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline; Prime Minister Takaichi's Policy Steps in Focus -- Market Talk

16.02.2026 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

BHP Shares Up 7.0% After Silver Streaming Deal, Profit Beat

16.02.2026 г., 23:20 ч. UTC

Придобивния, сливания и поглъщания

BHP Exploring Other Infrastructure Deals as It Chases $10 Billion Target - Interview

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Brokers Value BHP's Total Stake in Antamina Around $4.5 Billion

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Has Desalination, Other Power Assets on Which Deals Could Be Considered

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Wants to Make Sure It Does Not Give Up Any Strategic, Operational Control of Assets

16.02.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Will Allocate Cash From Asset Deals to Growth, Shareholder Returns

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Won't Put Deadline on $10 Billion Cash Unlock Target

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Bar Very High For Asset Deals

16.02.2026 г., 22:47 ч. UTC

Придобивния, сливания и поглъщания

BHP CFO: Sees 'Quite a Lot of Opportunities' in Potential Infrastructure Deals

16.02.2026 г., 22:35 ч. UTC

Пазарно говорене

Australian Jobs Data Could Confirm Market Too Tight -- Market Talk

16.02.2026 г., 22:02 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Net Profit, Dividend Rise; Signs $4.3 Billion Silver Streaming Deal

16.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Optimistic That Economic Backdrop Supportive For Key Commodities

16.02.2026 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals: Acquisition Immediately Increases Production and Cash Flow Profile

16.02.2026 г., 21:48 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: China's Economy Resilient; India Continues to Outperform

16.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Streaming, WAIO Power Deals Unlock Over $6 Billion of Cash Combined

16.02.2026 г., 21:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Sees Potential to Unlock Up to $10 Billion From Portfolio, Asset Management

16.02.2026 г., 21:47 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals to Have Combined 67.5% of All the Silver Produced From Antamina, Up From 33.75% Currently

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals: Upfront Payment to Be Funded Through Combination of Existing Liquidity and New Financing

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals Will Pay BHP Total Upfront Cash Consideration of $4.3B on Closing

16.02.2026 г., 21:46 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Interim Dividend Represents 60% Payout Ratio

16.02.2026 г., 21:46 ч. UTC

Придобивния, сливания и поглъщания

Wheaton Precious Metals in Definitive Precious Metals Purchase Agreement BHP Subsidiary for Its 33.75% Portion of Silver Produced at Antamina Mine in Peru

16.02.2026 г., 21:45 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP: Copper Contributed 51% of 1H Underlying Ebitda

16.02.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Net Debt $14.69 Billion at Dec. 31, Up 25% On-Year

16.02.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Net Operating Cash Flow $9.37 Billion, Up 13% On-Year

16.02.2026 г., 21:42 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Underlying Ebitda $15.46 Billion, Up 25% On-Year

16.02.2026 г., 21:42 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP Was Expected to Record Underlying Profit of $6.03 Billion According to Visible Alpha

16.02.2026 г., 21:41 ч. UTC

Печалби

Придобивния, сливания и поглъщания

BHP 1H Underlying Profit $6.20 Billion, Up 22% On-Year

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.